Sun-Jin Sym
Oncology Sun-Jin Sym Favorite Doctor
  • SpecialtyStomach cancer‚ Colorectal Cancer‚ Hepatobiliary biliary tract cancer‚ Tumor diseases of the gastrointestinal tract
  • Site
Appointment
Schedule
의료진 진료일정
Week M T W T F S
AM   Absent     Present  
PM   Absent Absent      
Clinical Interests

Gastric cancer, Colon cancer, Liver cancer, Pancreatic cancer, Biliary tract cancer, Gastrointestinal stromal tumor

Education
Education
Soon Chun Hyang University, BS in medicine
Ulsan University College of Medicine, MS
Ulsan University College of Medicine, Ph.D.
Career
Career
ASCO Travel Award
The Korean Cancer Association APCC Travel Award
Asian Clinical Oncology Society Kobayashi Foundation Award
More
Community
Community
The Korean Assocation of Internal Medicine
The Korean Cancer Association
The Korean Association for Clinical Oncology
Korean Cancer Study Group
The Korean Gastric Cancer Association
More
Training
Training
2015~2016 Mayo Clinic, Rochester, MN Training
License
License
M.D.
Internal Medicine Specialist
Hematologic Oncology Specialist
Sun-Jin Sym
Paper
Paper
2013 Sym SJ et al.A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer. 2013 NOV 8. Epub ahead of print
2012 Sym SJ et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol.Nov.29 2012 [Epub ahead of print]
2012 Sym SJ, Hong J, Jung M, Park J, Cho EK, Lee WK, Chung M, Kim HS, Shin DB. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.2012 Jun 30. Cancer Chemother Pharmacol [Epub ahead of print]
2009 Sun Jin Sym, Heung Moon Chang, Min-Hee Ryu, Jae-Lyun Lee, Tae-Won Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, and Yoon-Koo Kang. Neoadjuvant Docetaxel, Capecitabine and Cisplatin (DXP) in Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer. Ann Surg Oncol. Nov. 2009 [Epub ahead of Print]
2009 Kim TW, Ryu MH, Lee H, Sym SJ, Lee JL, Chang HM, Park YS, Lee KH, Kang WK, Shin DB, Bang YJ, Lee JS, Kang YL. Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumor: Oncologist, 2009 May 2 [Epub ahead of Print]
2009 Sun Jin Sym, Min-Hee Ryu, Hye Jin Kang, Sung Sook Lee, Heung-Moon Chang, Jae Lyun Lee, Tae Won Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, and Yoon-Koo Kang.Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin (DXO) combination chemotherapy in patients with previously untreated advanced gastric cancer.Cancer Chemother Pharmacol.Nov.2009 [Epub ahead of print]
2009 Park I, Lee JL, Ryu MH, Chang HM, Kim TW, Sym SJ, Lee SS, Jang G, Yoo C, Bae KS, Kang YK Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.Cancer Chemother Pharmacol. 2009 Jun 24. [Epub ahead of print]
2008 Sym SJ, Lee DH, Kang HJ, Nam SH, Kim Hoyoung, Kim JS, Eom HS, Kim WS, Suh CW. A multicenter phae II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (EHSAOx) for patients with primary refractroy/relapsed aggressive non-Hodgkin's lymphoma(NHL) Cancer Chemother Pharmacol.2008 Oct 7. [Epub ahead of print]
2008 Dose Escalation of Imatinib After Failure of Standard Dose in Korean Patients with Metastatic or Unresectabel Gastrointestinal Stromal Tumor.Jpn J Clin Oncol 2008 Dec 3.
2008 Sym SJ, Ryu MH, Lee J-L, Chagn HM, Kim TW, Kim HC, Kim KH, Yook JH, Kim BS, Kang YK. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stormal tumors (GISTs). J Surg Oncol.2008 Jul 1;98(1):27-33
2008 Sym SJ, Chang HM, Kang HJ, Lee SS, Ryu MH, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang Y-K. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol. 2008 Dec;63(1):1-8. Epub 2008 Feb 21.
2008 Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Lee SS, Lee JS, Kang YK. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol. 2008 Apr 31(2)
2008 Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Suh C. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol.2008 Jan;87(1)
2008 Lee JL, Ryu MH, Chang HM, Kim TW, Lee SS, Sym SJ, Kim MK, Lee JS, Kang YK. Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: A retrospective analysis. J Gastroenterol Hepatol. 2008 May;23(5):811-6. 2007 Nov 6; [Epub ahead of print]
2007 Jo JC, Lee J-L, Ryu MH, Sym SJ, Lee SS, Chang HM, Kim TW, Lee JS, Kang Y-K. Docetaxel monotherapy as a second-line treatement after failure of fluoropyrimidine and platinum in advanced gastric cancer: Experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol. 2007 Dec;37(12)
2007 Lee SS, Ahn JH, Kim MK, Sym SJ, Gong G, Ahn SD, Kim SB, Kim WK. Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat. 2007 Nov 8 [Epub ahead of print]
2007 Kim MK, Kim S, Jang G, Lee SS, Sym SJ, Lee DH, Kim SW, Jang S, Park CJ, Chi HS, Huh J, Suh C. A randomized comparison of peripheral blood hematopoietic progenitor cell level of 5/mm3 versus 50/mm3 as a surrogate marker to initiate efficient autologous blood stem cell collection. J Clin Apher. 2007 22(5)
2007 Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Kim SW, Jang S, Park CJ, Chi HS, Huh J, Suh C. Rituximab-ESHAP as a mobilixation regimen for relapsed or refractory B-cell lymphoma: a comparison with ESHAP. Transfusion. 2007 Aug;47(8)
2007 Jo JC, Lee DH, Kang BW, Lee SS, Sym SJ, Kim MK, Ahn JH, Lee JL, Kim SW, Suh C, Kang YK, Lee JS. Both-side intra-atrial intracardiac metastases as the initial presentation of testicular seminoma. Jpn J Clin Oncol. 2007 Jun;37(6)
2007 Lee SS, Kim MK, Sym SJ, Kim SW, Kim WK, Kim SB, Ahn JH. Intramedullary spinal cord metastases: a single-institution experience. J Neurooncol. 2007 Aug;84(1)
2007 Kim MK, Kim S, Lee SS, Sym SJ, Lee DH, Jang S, Park CJ, Chi HS, Huh J, Suh C. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol. 2007 Jun;86(6)
2007 Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Lee SS, Kim MK, Sym SJ, Lee JS, Kang YK. A phase II study of cetuximab (Erbitux(R)) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. J Korean Med Sci. 2007 Sep;22(Suppl)
2002 Sym SJ, Jung HY, Jo CL, Ji HS, Park TI, Park SR, Kim AY, Myung SJ, Ryu JS, Yang SK, Ha HK, Hong WS, Kim JH, Min YI. Predictors of outcome in patients with primary achalasia treated by pneumatic dilation. Korean J Gastrointest Endosc. 2002 Oct;25(4)
More